Ortin Global Ltd
ORTINGLOBE NSE
Ortin Global Ltd
HealthcareNSE: ORTINGLOBE BSE: 539287 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹13.01 Cr
Volatility
Moderate
P/E Ratio
-17.3
EBITDA
₹-1.04 Cr
Return on Equity
-42.8%
Debt to Equity
0.81
Book Value
₹1.53
52W High
₹21.3
52W Low
₹10.66
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Ortin Global Ltd insights
29 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Debtor days have improved from 260 to 178 days.
Weaknesses
9- Stock is trading at 10.4 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -45.0% over past five years.
- Promoter holding is low: 1.23%
- Company has a low return on equity of -72.7% over last 3 years.
- Contingent liabilities of Rs.24.3 Cr.
- Company might be capitalizing the interest cost
- Company has high debtors of 178 days.
- Promoter holding has decreased over last 3 years: -6.13%
Growth Rate
Revenue Growth
-75.00% ↘
Net Income Growth
-10.00% ↘
Cash Flow Change
91.44% ↗
ROE
-84.97% ↘
ROCE
-73.70% ↘
EBITDA Margin (Avg.)
-
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.57 | 0.27 | 0.14 | 0.3 | 0.21 | 0.05 | 0.03 | 0.09 | 0.08 | 0.01 | 0.01 | 0.3 | 0.01 |
| Expenses | 1.39 | 1.17 | 2.74 | 3.35 | 0.31 | 0.5 | 0.16 | 0.25 | 0.24 | 0.51 | 0.06 | 0.31 | 0.34 |
| Operating Profit | 0.18 | -0.9 | -2.6 | -3.05 | -0.1 | -0.45 | -0.13 | -0.16 | -0.16 | -0.5 | -0.05 | -0.01 | -0.33 |
| OPM % | 11.46% | -333.33% | -1857.14% | -1016.67% | -47.62% | -900% | -433.33% | -177.78% | -200% | -5000% | -500% | -3.33% | -3300% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0.11 | 0.15 | 0.14 | 0.08 | 0 | 0.02 | -0.01 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.06 | 0.06 | 0.06 | 0.05 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0.01 | -1.11 | -2.8 | -3.18 | -0.1 | -0.47 | -0.1 | -0.16 | -0.16 | -0.5 | -0.05 | -0.01 | -0.33 |
| Tax % | 0% | 1.8% | -0.71% | 30.19% | 0% | 0% | 10% | 0% | 6.25% | 0% | 0% | 0% | 0% |
| Net Profit | 0.02 | -1.12 | -2.79 | -4.14 | -0.1 | -0.47 | -0.11 | -0.16 | -0.18 | -0.5 | -0.05 | -0.01 | -0.34 |
| EPS in Rs | 0.02 | -1.38 | -3.43 | -5.09 | -0.12 | -0.58 | -0.14 | -0.2 | -0.22 | -0.61 | -0.06 | -0.01 | -0.42 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60.29 | 62.72 | 61.57 | 79.63 | 168 | 197 | 8.16 | 8.23 | 6 | 2.01 | 0.34 | 0.41 | 0.33 |
| Expenses | 53.8 | 56.83 | 56.12 | 74.22 | 161 | 192 | 6.92 | 7.85 | 5.47 | 6.4 | 1.23 | 1.13 | 1.22 |
| Operating Profit | 6.49 | 5.89 | 5.45 | 5.41 | 6.68 | 5.7 | 1.24 | 0.38 | 0.53 | -4.39 | -0.89 | -0.72 | -0.89 |
| OPM % | 10.76% | 9.39% | 8.85% | 6.79% | 3.99% | 2.89% | 15.2% | 4.62% | 8.83% | -218.41% | -261.76% | -175.61% | -269.7% |
| Other Income | 0 | 0.57 | 0.32 | 0.45 | 0.13 | 0.18 | 0.05 | 0.19 | 0.01 | -1.98 | 0.06 | 0 | 0 |
| Interest | 3.52 | 3.42 | 2.94 | 3.49 | 3.22 | 3.21 | 0.87 | 0.81 | 0.4 | 0.48 | 0 | 0 | 0 |
| Depreciation | 1.64 | 1.65 | 1.7 | 1.69 | 1.75 | 1.96 | 0.29 | 0.29 | 0.25 | 0.23 | 0.01 | 0 | 0 |
| PBT | 1.33 | 1.39 | 1.13 | 0.68 | 1.84 | 0.71 | 0.13 | -0.53 | -0.11 | -7.08 | -0.84 | -0.72 | -0.89 |
| Tax % | 32.33% | 41.01% | 55.75% | 0% | 30.43% | 181.69% | -623.08% | -24.53% | -18.18% | 13.56% | 1.19% | 2.78% | — |
| Net Profit | 0.9 | 0.83 | 0.5 | 0.68 | 1.28 | -0.56 | 0.95 | -0.4 | -0.09 | -8.04 | -0.85 | -0.74 | -0.9 |
| EPS in Rs | 0.53 | 0.49 | 0.3 | 0.4 | 0.76 | -0.33 | 1.17 | -0.49 | -0.11 | -9.89 | -1.05 | -0.91 | -1.1 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 8.13 | 8.13 | 8.13 | 8.13 | 8.13 | 8.13 |
| Reserves | 5.5 | 6.33 | 6.46 | 7.14 | 8.15 | 6.88 | 3.22 | 2.83 | 2.73 | -5.31 | -6.15 | -6.89 |
| Borrowings | 20.96 | 20.85 | 17.34 | 17.34 | 19.47 | 19.57 | 6.94 | 6.14 | 6.45 | 1.8 | 0.25 | 1.01 |
| Other Liabilities | 23.87 | 21.22 | 20.79 | 32.24 | 60.53 | 73.13 | 2.97 | 3.61 | 3.89 | 2.05 | 1.55 | 2.4 |
| Total Liabilities | 67.27 | 65.34 | 61.53 | 73.66 | 105 | 117 | 21.26 | 20.71 | 21.2 | 6.67 | 3.78 | 4.65 |
| Fixed Assets | 21.83 | 21.63 | 20.69 | 20.03 | 21.29 | 22.45 | 14.38 | 14.21 | 13.96 | 0.01 | 0 | 0.01 |
| CWIP | 0 | 0 | 0.35 | 0.4 | 0.53 | 0.43 | 0.43 | 0.43 | 0.43 | 0 | 0 | 0 |
| Investments | 0.03 | 0.03 | 0.07 | 0.08 | 0.08 | 0.07 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 45.41 | 43.68 | 40.42 | 53.15 | 83.19 | 93.57 | 6.45 | 6.07 | 6.81 | 6.66 | 3.78 | 4.64 |
| Total Assets | 67.27 | 65.34 | 61.53 | 73.66 | 105 | 117 | 21.26 | 20.71 | 21.2 | 6.67 | 3.78 | 4.65 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -1.38 | 0.52 | 1.94 | 1.56 | 6.52 | 3.3 | 18.03 | 2.15 | -0.25 | -4.79 | -0.41 | -0.56 |
| Investing | 0.22 | -0.86 | -1.26 | -0.9 | -3.27 | -3.09 | 0.07 | -0.13 | 0.01 | 12 | 0 | 0.04 |
| Financing | 1.73 | 0.27 | -0.82 | 0.07 | -2.89 | -1.33 | -9.86 | -0.48 | 0.9 | -3.49 | 0.33 | 0.75 |
| Net Cash Flow | 0.58 | -0.07 | -0.14 | 0.73 | 0.37 | -1.12 | 8.25 | 1.55 | 0.66 | 3.72 | -0.09 | 0.23 |
| Free Cash Flow | -1.38 | -0.92 | 0.83 | 0.77 | 3.38 | 0.28 | 18.03 | 2.02 | -0.24 | 7.21 | -0.41 | -0.52 |
| CFO/OP | -14 | 17 | 47 | 40 | 104 | 72 | 1,454 | 566 | -47 | 80 | 46 | 78 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 53.13 | 90.35 | 100 | 82.43 | 68.71 | 175 | 144 | 208 | 321 | 279 | 178 |
| Inventory Days | 192 | 149 | 158 | 152 | 100 | 118 | 169 | 136 | 280 | 4.92 | 34.76 | 0 |
| Days Payable | 151 | 24.82 | 108 | 143 | 145 | 156 | 124 | 61.88 | 167 | 7.87 | 69.52 | — |
| Cash Conversion Cycle | 145 | 177 | 140 | 109 | 37.38 | 30.7 | 220 | 218 | 321 | 318 | 244 | 178 |
| Working Capital Days | 29 | 16.24 | 37.29 | 41.48 | 16.82 | 11.24 | -87.22 | -109 | -43.19 | 358 | 1,524 | 730 |
| ROCE % | 12.07% | 10.92% | 9.57% | 9.44% | 11.77% | 8.94% | 3.24% | 1.58% | 1.8% | -40.58% | -25.11% | -32.14% |
Documents
1
Unaudited Financial Results For The Quarter Ended 30.06.2026
14 Aug - Board approved unaudited Q1 FY2026-27 results on 14.08.2026; loss widened to Rs 33.79 lakh. 14 Aug - Board approved unaudited Q1 FY2026-27 results on 14.08.2026; loss widened to Rs 33.79 lakh.
2
Board Meeting Outcome for Outcome Of Board Meeting Held On 14.08.2026
14 Aug - Board approved unaudited Q1 FY2026-27 results; net loss Rs 33.79 lakh, limited review completed. 14 Aug - Board approved unaudited Q1 FY2026-27 results; net loss Rs 33.79 lakh, limited review completed.
4
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
30 Apr - Ortin Global says it is not a Large Corporate for FY2025-26; debt borrowing nil. 30 Apr - Ortin Global says it is not a Large Corporate for FY2025-26; debt borrowing nil.
5
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
6 May - Ortin Global confirms it is not a Large Corporate for FY 2026-27. 6 May - Ortin Global confirms it is not a Large Corporate for FY 2026-27.
Frequently Asked Questions about Ortin Global Ltd
What does Ortin Global Ltd do?
Incorporated in 1986, Ortin Laboratories Ltd manufactures pharmaceutical formulations.[1]
Where is Ortin Global Ltd (ORTINGLOBE) listed?
Ortin Global Ltd is listed on the Indian stock exchanges. It is listed on NSE: ORTINGLOBE and BSE: 539287. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Ortin Global Ltd belong to?
Ortin Global Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Ortin Global Ltd?
Ortin Global Ltd has a market capitalisation of approximately ₹13.01 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Ortin Global Ltd?
The Price-to-Earnings (PE) ratio of Ortin Global Ltd is -17.30. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Ortin Global Ltd?
Over the past 52 weeks, Ortin Global Ltd has traded between a low of ₹10.66 and a high of ₹21.3. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Ortin Global Ltd?
Ortin Global Ltd has a Return on Equity (ROE) of -42.80%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Ortin Global Ltd on Tapetide?
On Tapetide, you can view Ortin Global Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1986, Ortin Laboratories Ltd manufactures pharmaceutical formulations.[1]